Bayer Schering Oncology Candidate Becomes First Syndax Pipeline Compound
This article was originally published in The Pink Sheet Daily
Executive Summary
Biopharma inlicenses Bayer’s selective histone deacetylase inhibitor to develop in combination therapies.